We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Chinese expert consensus on whole-process management of oxaliplatin-induced hypersensitivity reactions (2024 edition): Cancer Assessment Society of China Anti-Cancer Association, Cancer Pain Society of Fujian Anti-Cancer Association.
- Authors
LIN Rongbo
- Abstract
Oxaliplatin serves as a basic therapeutic agent for various malignant tumors. Oxaliplatin-induced hypersensitivity reactions are potentially life-threatening, and frequently lead to treatment discontinuation. Alternative therapies may be less effective and/or more expensive, with varying tolerability. Oxaliplatin hypersensitivity reactions typically manifest as a classic type I allergy, as well as cytokine release reactions and mixed types. In clinical practice, management of anaphylaxis and questions relative to rechallenge with oxaliplatin after occurrence of hypersensitivity reactions are of utmost concern. Therefore, based on evidence-based medicine and clinical practice experience, the expert panel carried out a comprehensive assessment and discussion on the definition, clinical characteristics, diagnosis, classification and grading criteria, management, and rechallenge of hypersensitivity reactions to oxaliplatin. Eventually, the "Chinese expert consensus on whole-process management of oxaliplatin-induced hypersensitivity reactions (2024 edition)" was formulated to further standardize the whole-process management of oxaliplatin-induced hypersensitivity reactions. The consensus has been registered on Practice guideline REgistration for transPAREncy (PREPARE) with the registration number PREPARE-2024CN371.
- Subjects
TERMINATION of treatment; CANCER pain; EVIDENCE-based medicine; CLINICAL medicine; ANAPHYLAXIS
- Publication
China Oncology, 2024, Vol 34, Issue 8, p785
- ISSN
1007-3639
- Publication type
Article
- DOI
10.19401/j.cnki.1007-3639.2024.08.008